AMGN · News · 20260913N

IMDELLTRA Pipeline Progress

AMGEN INC · 2026-09-13 · Importance 34 · Surprise 42

Third-party reporting cited new Phase 3 IMDELLTRA data in lung cancer showing improved overall survival and progression-free survival. The data may strengthen Amgen’s 2027 growth narrative and reshape investor expectations for the oncology product. The report also noted regulatory uncertainties and manufacturing-capacity risks related to Amgen’s obesity-drug program, without quantifying their financial impact.

Key facts

• Amgen has new Phase 3 IMDELLTRA data showing improved overall and progression-free survival in lung cancer. source
• One valuation model suggests Amgen is slightly overvalued at $359.98 while another Discounted Cash Flow model indicates Amgen is significantly undervalued at $669.81. source